CHEGAEV, Konstantin
 Distribuzione geografica
Continente #
NA - Nord America 4.976
EU - Europa 2.768
AS - Asia 1.305
SA - Sud America 31
AF - Africa 26
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 6
Totale 9.132
Nazione #
US - Stati Uniti d'America 4.901
CN - Cina 864
IT - Italia 729
IE - Irlanda 462
SE - Svezia 297
DE - Germania 277
FR - Francia 186
UA - Ucraina 171
FI - Finlandia 144
PL - Polonia 127
GB - Regno Unito 118
AT - Austria 108
KR - Corea 100
JP - Giappone 69
CA - Canada 67
IN - India 63
VN - Vietnam 60
TW - Taiwan 39
RU - Federazione Russa 30
ES - Italia 28
BE - Belgio 26
TR - Turchia 22
HK - Hong Kong 20
BR - Brasile 19
NL - Olanda 19
SG - Singapore 11
AU - Australia 10
NZ - Nuova Zelanda 10
EG - Egitto 9
GR - Grecia 8
JO - Giordania 8
MX - Messico 8
SN - Senegal 7
CH - Svizzera 6
EU - Europa 6
IR - Iran 6
MY - Malesia 6
TH - Thailandia 6
AE - Emirati Arabi Uniti 5
AR - Argentina 5
BG - Bulgaria 5
ID - Indonesia 5
PT - Portogallo 5
NG - Nigeria 4
NO - Norvegia 4
RO - Romania 4
UZ - Uzbekistan 4
CL - Cile 3
CY - Cipro 3
DK - Danimarca 3
HU - Ungheria 3
IQ - Iraq 3
MU - Mauritius 3
AF - Afghanistan, Repubblica islamica di 2
AM - Armenia 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
EC - Ecuador 2
HR - Croazia 2
IL - Israele 2
PK - Pakistan 2
QA - Qatar 2
SI - Slovenia 2
UY - Uruguay 2
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
ZA - Sudafrica 1
Totale 9.132
Città #
Ann Arbor 505
Fairfield 501
Chandler 466
Dublin 457
Beijing 431
Ashburn 352
Houston 251
Woodbridge 220
Torino 218
Wilmington 196
Seattle 173
Dearborn 160
Pisa 152
Cambridge 150
Villeurbanne 121
Jacksonville 120
Warsaw 118
Nyköping 115
Medford 107
Vienna 104
Princeton 93
Redwood City 84
Fremont 69
Munich 38
Boston 34
Shanghai 34
Taipei 34
Guangzhou 30
Hangzhou 29
Dong Ket 28
Milan 27
Brussels 26
San Diego 26
New York 25
Toronto 24
Nanjing 23
Zhengzhou 22
Ottawa 21
Siena 21
Tokyo 21
Turin 21
Jinan 20
Washington 20
Boardman 19
Verona 19
Norwalk 18
Wuhan 17
Kunming 16
Toledo 15
Shenyang 12
Hanover 11
Upper Marlboro 11
Xian 11
Changsha 10
Florence 10
Hefei 9
Nürnberg 9
Phoenix 9
Rome 9
Chengdu 8
Falls Church 8
Hebei 8
Nanchang 8
Philadelphia 8
Pune 8
Silver Spring 8
Buffalo 7
Changchun 6
Dallas 6
Farmington 6
Lachine 6
Moscow 6
Nanning 6
Tianjin 6
Amman 5
Bari 5
Catania 5
Chioggia 5
Chongqing 5
Des Moines 5
Fort Lauderdale 5
Granada 5
Leinì 5
London 5
Rivoli 5
San Jose 5
Tappahannock 5
Woodside 5
Abuja 4
Ankara 4
Bangkok 4
Bologna 4
Buenos Aires 4
Cairo 4
Central District 4
Fuzhou 4
Monmouth Junction 4
Mountain View 4
Nashville 4
Nottingham 4
Totale 6.115
Nome #
H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance 396
Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance 274
New furoxan derivatives for the treatment of ocular hypertension 265
Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts 261
Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance. 257
NO-donor thiacarbocyanines as multifunctional agents for Alzheimer’s disease 253
Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins 248
Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors 245
Doxorubicin-antioxidant multitarget drugs 242
Edaravone derivatives containing NO-donor functions 205
(Nitrooxyacyloxy)methyl esters of aspirin as novel nitric oxide releasing aspirins 200
Galactosylated Pro-Drug of Ursodeoxycholic Acid: Design, Synthesis, Characterization, and Pharmacological Effects in a Rat Model of Estrogen-Induced Cholestasis 172
Phenylsulfonylfuroxans as Modulators of Multidrug-Resistance-Associated Protein-1 and P-Glycoprotein 169
Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis 166
Liposomal Nitrooxy-Doxorubicin: One Step over Caelyx in Drug-Resistant Human Cancer Cells 165
New nitric oxide or hydrogen sulfide releasing aspirins 164
Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs 162
Solid lipid nanoparticles carrying lipophilic derivatives of doxorubicin: preparation, characterization, and in vitro cytotoxicity studies 157
Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity 156
Furazan and furoxan sulfonamides are strong α-carbonic anhydrase inhibitors and potential antiglaucoma agents 155
Development of a new class of potential antiatherosclerosis agents: NO-donor antioxidants 154
Effects of Nitric Oxide Donor Antioxidants Containing the Phenol Vitamin E Substructure and a Furoxan Moiety on Ischemia/Riperfusion Injury 148
Direct introduction of cyano group on furoxan ring 135
gem-Dinitroalkyl Benzenes: A Novel Class of IOP-Lowering Agents for the Treatment of Ocular Hypertension 135
NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties 129
Solid Lipid Nanoparticles Loaded with Antitumor Lipophilic Prodrugs Aimed to Glioblastoma Treatment: Preliminary Studies on Cultured Cells 126
A Nitric Oxide-Donor Furoxan Moiety Improves the Efficacy of Edaravone against Early Renal Dysfunction and Injury Evoked by Ischemia/Reperfusion 122
Amphiphilic NO-Donor Antioxidants 120
Synthesis and Biological Evaluation of N2-Substituted 2,4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and Related 5-Cyano-NNO-azoxy Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors 120
Novel Antioxidant Agents Deriving From Molecular Combination of Vitamin C and NO-donor moieties 115
Multitarget Drugs: Focus on the NO-donor hybrid drugs 114
NO-Donor Melatonin Derivatives: Synthesis And In Vitro Pharmacological Characterization 114
Nitric Oxide Donor Doxorubicins Accumulate into Doxorubicin-Resistant Human Colon Cancer Cells Inducing Cytotoxicity 113
Synthesis of Some Novel Organic Nitrates and Comparative in Vitro Study of Their Vasodilator Profile 108
Structural and biological characterization of new hybrid drugs joining an HDAC inhibitor to different NO-donors 105
Aceclofenac-galactose conjugate: design, synthesis, characterization and pharmacological and toxicological evaluations 102
New tetrahydroisoquinoline derivatives overcome pgp activity in brain-blood barrier and glioblastoma multiforme in vitro 100
NO-Donor Phenols: A New Class of Products Endowed with Antioxidant and Vasodilator Properties 99
Mitochondrial delivery of phenol substructure triggers mitochondrial depolarization and apoptosis of cancer cells 93
Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma 92
Leishmanicidal Activity of Novel Synthetic Furoxan and Benzofuroxan Derivatives 89
Novel Organic Nitrate Esters 82
New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations 80
New tetrahydroisoquinoline-based P-glycoprotein modulators: Decoration of the biphenyl core gives selective ligands 80
Evaluation of the targeting ability of folate containing liposomal nitrooxy-doxorubicin. 79
Paracetamol-Galactose Conjugate: A Novel Prodrug for an Old Analgesic Drug 79
NO-Donor Furoxans Containing a Sulphonamide Moiety and Related Furazans as Potent Carbonic Anhydrase Inhibitors 77
Amphiphile NO-donor antioxidants as polivalent drugs 76
Nitrooxy-doxorubicin: A New Weapon Against Multidrug Resistance. 74
PREPARATION AND CHARACTERIZATION OF LIPOSOMES CONTAINING A NEW ANTHRACYCLINE DERIVATIVE 72
NITRIC OXIDE DONOR DOXORUBICINS: A USEFUL STRATEGY TO ADDRESS THE PROBLEM OF MDR IN CANCER THERAPY 70
Highly diastereoselective synthesis of 2-monosubstituted 1R,5S(1S,5R)-glycoluriles on the basis of S- and R-N-carbamoyl-alpha-amino acids 68
MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells 67
Synthesis of new heterocyclic sulfamides 66
Multitarget Drugs: No-Donor Doxorubicins 65
Novel amphiphilic nitric oxide releasing antioxidants: NMR spectroscopic study of their interaction with biomembrane models 64
NO-Donor Cyanines As Potential Anti-Alzheimer Drugs 63
Reactions of sulfonamides with 4,5-dihydroxyimidazolidin-2-ones 59
PHENYLSULFONYL FUROXANS AS MODULATORS OF MULTIDRUGRESISTANCE-ASSOCIATED PROTEIN-1 AND P-GLYCOPROTEIN 58
INCAPSULATED NO-GEMCITABINE: GASEOUS SOLUTION FOR MDR PANCREATIC CANCER 58
Novel NO-donor Doxorubicins 56
MODIFIED DOXORUBICINS: "GASEOUS APPROACH" TO OVERCOME CARDIOTOXICITY AND MULTIDRUG RESISTANCE 56
Unsymmetrically Substituted Furoxans. Part 19. Methyl and Phenylfuroxansulfonic Acids and Related Sulfonamides 54
Low concentrations of an nitric oxide-donor combined with a liposoluble antioxidant compound enhance protection against reperfusion injury in isolated rat hearts 54
NOVEL SEMISYNTHETIC DOXORUBICINS WITH REDUCED CARDIOTOXICITY 54
Discovery of phenylsulfonylfuroxan derivatives as gamma globin inducers by histone acetylation 54
NO donor - melatonins: a new class of potential antiatherosclerosis agents 53
A Comprehensive Evaluation of Sdox, a Promising H2S-Releasing Doxorubicin for the Treatment of Chemoresistant Tumors 51
Vasodilating profile of a new series of analogues of GTN 50
Multitarget drugs: NO-donor doxorubicins 49
New functional glycoluril derivatives 48
Preparation and characterization of liposomes containing a new anthracycline derivative. 48
Synthesis, chiral HPLC resolution and configuration assignment of 1-phenylglyceryl trinitrate stereomers 47
The N-silylation reaction of 2,4,6-trialkyl-2,4,6,8-tetraazabicyclo[3.3.0]octane-3,7-diones 47
Tolerance profile of new organic nitrates with antioxidant properties 45
Screening for potential hazard effects from a multitarget anthracycline on the cardiovascular system 45
Synthesis of 2-monofunctionalized 2,4,6,8-tetraazabicyclo[3.3.0]octane-3,7-diones 43
Nitric oxide release by an edavarone derivative containing NOdonor furoxan moiety contributes to the resolution of renal injury after ischemia/reperfusion in the rat 41
Nitric oxide donor-doxorubicins as mdr reversing agents 40
MITOCHONDRIAL-TARGETING NITROOXYDOXORUBICIN: EFFECTS ON P-GLYCOPROTEIN AND ASSESSMENT OF THEIR VASCULAR EFFECTS 39
Structure-Activity Relationship Studies on Tetrahydroisoquinoline Derivatives: [4′-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-ol] (MC70) Conjugated through Flexible Alkyl Chains with Furazan Moieties Gives Rise to Potent and Selective Ligands of P-glycoprotein 38
IN VITRO CARDIOVASCULAR TOXICITY RISK ASSESSMENT OF NOVEL H2S-DONATING ANTHRACYCLINE 37
Reactions of N-alkylglycolurils with electrophilic reagents 37
Planning, synthesis and anti-Mycobacterium tuberculosis activity of N-oxide derivatives 33
NO-donor aspirin derivatives 32
Screening for potential hazard effects from multitarget anthracyclines on vasculature 31
SCREENING FOR POTENTIAL HAZARD EFFECTS FROM MULTITARGET ANTHRACYCLINE ON THE CARDIOVASCULAR SYSTEM 30
Synthesis, physical-chemical and pharmacological studies of new organic nitrates as novel potent vasodilatators 28
NO release regulated by doxorubicin as the green light-harvesting antenna 25
Multitarget antioxidant NO-donor organic nitrates: a novel ap-proach to overcome nitrates tolerance, an ex vivo study 22
N-[1,3-Dialkyl(aryl)-2-oxoimidazolidin-4-ylidene]-aryl(alkyl)sulphonamides as Novel Selective Human Cannabinoid Type 2 Receptor (hCB2R) Ligands; Insights into the Mechanism of Receptor Activation/Deactivation 21
Naked and Decorated Nanoparticles Containing H2S-Releasing Doxorubicin: Preparation, Characterization and Assessment of Their Antitumoral Efficiency on Various Resistant Tumor Cells 19
Comparative Study of Different H2S Donors as Vasodilators and Attenuators of Superoxide-Induced Endothelial Damage 15
In vitro vascular toxicity assessment of NitDOX, a novel NO-releasing doxorubicin 14
New lipophilic organic nitrates: Candidates for chronic skin disease therapy 9
Multitarget antioxidant NO-donor organic nitrates: a novel approach to overcome nitrates tolerance 7
Use of Enzymatically Activated Carbon Monoxide Donors for Sensitizing Drug-Resistant Tumor Cells 5
Sdox, a H2S releasing anthracycline, with a safer profile than doxorubicin toward vasculature 5
Totale 9.464
Categoria #
all - tutte 22.751
article - articoli 0
book - libri 0
conference - conferenze 4.328
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.079


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019582 0 0 0 0 0 0 0 0 39 102 322 119
2019/20201.669 58 67 93 220 98 220 165 131 198 181 130 108
2020/20211.180 98 92 86 63 115 74 65 86 170 114 83 134
2021/20221.403 87 84 99 133 69 49 101 87 59 88 322 225
2022/20231.601 148 145 32 118 113 374 261 89 161 57 61 42
2023/2024655 91 132 57 38 73 168 42 42 12 0 0 0
Totale 9.464